-
Je něco špatně v tomto záznamu ?
Cellular and humoral immune responses to chimeric EGFP-pseudocapsids derived from the mouse polyomavirus after their intranasal administration
J Fric, M Marek, V Hruskova, V Holan, J Forstova
Jazyk angličtina Země Nizozemsko
NLK
ProQuest Central
od 2002-01-01 do Před 2 měsíci
Nursing & Allied Health Database (ProQuest)
od 2002-01-01 do Před 2 měsíci
Health & Medicine (ProQuest)
od 2002-01-01 do Před 2 měsíci
Family Health Database (ProQuest)
od 2002-01-01 do Před 2 měsíci
Health Management Database (ProQuest)
od 2002-01-01 do Před 2 měsíci
Public Health Database (ProQuest)
od 2002-01-01 do Před 2 měsíci
ScienceDirect (archiv)
od 1993-01-01 do 2009-12-31
- MeSH
- aplikace intranazální MeSH
- cytotoxické T-lymfocyty imunologie MeSH
- cytotoxické testy imunologické MeSH
- financování organizované MeSH
- interferon gama biosyntéza MeSH
- interleukin-2 biosyntéza MeSH
- krev imunologie MeSH
- lymfatické uzliny imunologie MeSH
- myši MeSH
- Polyomavirus imunologie MeSH
- proliferace buněk MeSH
- protilátky virové krev MeSH
- rekombinantní fúzní proteiny aplikace a dávkování imunologie MeSH
- slezina imunologie MeSH
- T-lymfocyty - podskupiny imunologie MeSH
- T-lymfocyty imunologie MeSH
- vakcíny VLP aplikace a dávkování imunologie MeSH
- virové plášťové proteiny aplikace a dávkování imunologie MeSH
- zelené fluorescenční proteiny imunologie MeSH
- zvířata MeSH
- Check Tag
- myši MeSH
- ženské pohlaví MeSH
- zvířata MeSH
Mouse polyomavirus (MPyV) VP1-pseudocapsids carrying enhanced green fluorescent protein (EGFP-VLPs) were used for intranasal immunization of mice. EGFP-VLPs induced strong anti-VP1 but not anti-EGFP antibody production. In vitro restimulation with antigen-pulsed bone marrow-derived dendritic cells (BMDCs) induced remarkable T-cell proliferative response specific for both VP1 and EGFP antigen and IL-2 and IFN-gamma production. Surprisingly, no specific cytotoxic activities against VP1 and EGFP proteins were detected. After intranasal administration of EGFP-VLPs, as well as after polyomavirus infection, a moderate reduction of CD4(+)CD25(+)Foxp3(+) T cells was observed in spleens but not in lymph nodes and peripheral blood, suggesting that both MPyV virions and pseudocapsids are able to induce changes in distribution of regulatory T cells. Treatment of EGFP-VLPs pulsed BMDCs with inhibitors of endosomal acidification proved that presentation of peptides on MHCgp class II is dependent on acidic endosomal environment. Substantial decrease of CD4-specific T-cell proliferation in the presence of proteasome inhibitor suggests that MHCgp class II might load VPL-derived peptides processed by proteasomes. Thus, polyomavirus derived VLPs appear to be promising delivery and adjuvant vehicles for therapeutic proteins.
Citace poskytuje Crossref.org
- 000
- 03413naa 2200529 a 4500
- 001
- bmc11004112
- 003
- CZ-PrNML
- 005
- 20121130100154.0
- 008
- 110303s2008 ne e eng||
- 009
- AR
- 024 __
- $a 10.1016/j.vaccine.2008.04.006 $2 doi
- 035 __
- $a (PubMed)18468739
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Frič, Jan $7 xx0106155
- 245 10
- $a Cellular and humoral immune responses to chimeric EGFP-pseudocapsids derived from the mouse polyomavirus after their intranasal administration / $c J Fric, M Marek, V Hruskova, V Holan, J Forstova
- 314 __
- $a Faculty of Science, Charles University in Prague, Prague 2, Czech Republic.
- 520 9_
- $a Mouse polyomavirus (MPyV) VP1-pseudocapsids carrying enhanced green fluorescent protein (EGFP-VLPs) were used for intranasal immunization of mice. EGFP-VLPs induced strong anti-VP1 but not anti-EGFP antibody production. In vitro restimulation with antigen-pulsed bone marrow-derived dendritic cells (BMDCs) induced remarkable T-cell proliferative response specific for both VP1 and EGFP antigen and IL-2 and IFN-gamma production. Surprisingly, no specific cytotoxic activities against VP1 and EGFP proteins were detected. After intranasal administration of EGFP-VLPs, as well as after polyomavirus infection, a moderate reduction of CD4(+)CD25(+)Foxp3(+) T cells was observed in spleens but not in lymph nodes and peripheral blood, suggesting that both MPyV virions and pseudocapsids are able to induce changes in distribution of regulatory T cells. Treatment of EGFP-VLPs pulsed BMDCs with inhibitors of endosomal acidification proved that presentation of peptides on MHCgp class II is dependent on acidic endosomal environment. Substantial decrease of CD4-specific T-cell proliferation in the presence of proteasome inhibitor suggests that MHCgp class II might load VPL-derived peptides processed by proteasomes. Thus, polyomavirus derived VLPs appear to be promising delivery and adjuvant vehicles for therapeutic proteins.
- 650 _2
- $a aplikace intranazální $7 D000281
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a protilátky virové $x krev $7 D000914
- 650 _2
- $a krev $x imunologie $7 D001769
- 650 _2
- $a virové plášťové proteiny $x aplikace a dávkování $x imunologie $7 D036022
- 650 _2
- $a proliferace buněk $7 D049109
- 650 _2
- $a cytotoxické testy imunologické $7 D003601
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a zelené fluorescenční proteiny $x imunologie $7 D049452
- 650 _2
- $a interferon gama $x biosyntéza $7 D007371
- 650 _2
- $a interleukin-2 $x biosyntéza $7 D007376
- 650 _2
- $a lymfatické uzliny $x imunologie $7 D008198
- 650 _2
- $a myši $7 D051379
- 650 _2
- $a Polyomavirus $x imunologie $7 D011120
- 650 _2
- $a rekombinantní fúzní proteiny $x aplikace a dávkování $x imunologie $7 D011993
- 650 _2
- $a slezina $x imunologie $7 D013154
- 650 _2
- $a T-lymfocyty - podskupiny $x imunologie $7 D016176
- 650 _2
- $a T-lymfocyty $x imunologie $7 D013601
- 650 _2
- $a cytotoxické T-lymfocyty $x imunologie $7 D013602
- 650 _2
- $a vakcíny VLP $x aplikace a dávkování $x imunologie $7 D022721
- 650 _2
- $a financování organizované $7 D005381
- 700 1_
- $a Marek, Martin. $7 _AN029554
- 700 1_
- $a Hrušková, Veronika. $7 xx0228115
- 700 1_
- $a Holáň, Vladimír, $d 1950- $7 nlk20050169384
- 700 1_
- $a Forstová, Jitka, $d 1944- $7 xx0057861
- 773 0_
- $t Vaccine $w MED00004631 $g Roč. 26, č. 26 (2008), s. 3242-3251 $x 0264-410X
- 910 __
- $a ABA008 $b x $y 1
- 990 __
- $a 20110414092513 $b ABA008
- 991 __
- $a 20121130100223 $b ABA008
- 999 __
- $a ok $b bmc $g 831451 $s 696140
- BAS __
- $a 3
- BMC __
- $a 2008 $b 26 $c 26 $d 3242-3251 $i 0264-410X $m Vaccine $n Vaccine $x MED00004631
- LZP __
- $a 2011-3B/ipme